Formoterol monotherapy compared with combined ipratropium bromide plus fenoterol in the treatment of chronic obstructive pulmonary disease

Clinical Drug Investigation

Volumn 21, Issue 4, 2001, Pages 235-242

  Konermann, M ^a   Suchantke, R ^a   Mogck, J ^a   Brauburger, J ^b   Brautigam M ^b  

^a Marienkrankenhaus Kassel ^*  (Germany)

^b Novartis Pharma GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FENOTEROL; FENOTEROL PLUS IPRATROPIUM BROMIDE; FORMOTEROL; FORMOTEROL FUMARATE; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; AIRWAY RESISTANCE; ARTICLE; CARDIOTOXICITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MIXTURE; DRUG TOLERABILITY; FEMALE; FORCED EXPIRATORY VOLUME; GASTROINTESTINAL DISEASE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROLOGIC DISEASE; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; TOTAL LUNG CAPACITY; VITAL CAPACITY;

EID: 0035062338     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200121040-00001     Document Type: Article

References (24)

1. Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease
2. Incidence, prevalence and mortality: Intra- and inter-country differences
3. Die chronische bronchitis und ihre folgen
4. Longitudinal changes in forced expiratory volume in one second in adults: Effects of smoking and smoking cessation
5. Pulmonary disease in alpha-1-antitrypsin deficiency
6. Empfehlungen der deutschen atemwegsliga zur behandlung von patienten mit chronisch obstruktiver bronchitis und lungenemphysem
7. Management 1997 of chronic obstructive pulmonary disease
8. Effects of smoking intervention and the use of inhaled anticholinergic bronchodilator on the rate of decline on FEV1
9. A comparison of the bronchodilating effects of a beta-2 adrenergic agent (albuterol) and an anticholinergic agent (ipratropium bromide), given by aerosol alone or in sequence
10. Bronchodilating effects of combined therapy with clinical dosages of ipratropium bromide and salbutamol for stable COPD: Comparison with ipratropium bromide alone
11. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial
12. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD
13. Therapeutische optionen im management der stabilen chronisch obstruktiven lungenerkrankung (COPD)
14. Evaluation of the intensity and duration of the bronchodilatory action of fenoterol - Ipratropium bromide in combination compared with terbutaline and placebo in patients with chronic obstructive lung disease
15. Global initiative for asthma (GINA) and its objectives
16. Formoterol dry powder improves the quality of life of patients with COPD whereas the effect of ipratropium bromide is similar to placebo
17. Onset of action of inhaled formoterol compared to ipratropium bromide in patients with COPD
18. Effect of inhaled formoterol and oral slow-release theophylline on peak expiratory flow and symptoms in patients with COPD
19. Pharmacotherapy in COPD
20. Multiple dose regimens; impact on compliance
21. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma
22. Effects of regular salmeterol on lung function and exercise capacity in patients with obstructive airways disease
23. Plethysmographic parameters in the assessment of reversibility of airways obstruction in patients with clinical emphysema
24. Which test best measures bronchodilator drug response in patients with loss of lung elasticity?